FDC Q1 Revenue at Rs 6.48 Billion, Margins Dip Slightly

08 Aug 2025 CW Team

FDC Limited has reported a steady performance for the quarter ended 30 June 2025 (Q1 FY26), with operating revenue of Rs 6.48 billion, reflecting a year-on-year (YoY) growth of 1.6 per cent.

The India formulation business recorded revenue of Rs 5.79 billion, showing a 5.6 per cent YoY rise and contributing 90 per cent to total consolidated sales. The API segment also delivered modest growth of 3.3 per cent YoY, with sales of Rs 260 million. However, export formulations dropped 33.8 per cent YoY to Rs 420 million, while emerging market revenue declined 39 per cent YoY to Rs 260 million due to supply disruptions.

The US business showed early signs of recovery, with Rs 116 million in sales during Q1 FY26, representing a 106 per cent YoY growth in direct supplies. This growth follows the resolution of recall-related issues and updated API impurity standards clarified by the US FDA. Despite this progress, overall US business revenue fell 22.2 per cent YoY due to lower profit share from partners caused by reduced sales in FY25.

FDC’s EBITDA for the quarter stood at Rs 1.4 billion, with a margin of 21.6 per cent, down from 23 per cent in the previous year. The drop is mainly due to increased strategic expenses, notably a 271.4 per cent YoY surge in R&D expenditure to Rs 85 million and higher employee costs linked to field force expansion and ORS manufacturing capacity enhancements.

Business Performance Summary – Q1 FY26 (Rs crore):

Net Sales: Rs 648 crore | 1.6% YoY growth
India Formulations: Rs 579 crore | 5.6% YoY growth
US Formulations: Rs 16 crore | -22.2% YoY decline
Emerging Markets: Rs 26 crore | -39.3% YoY decline
API Sales: Rs 26 crore | 3.3% YoY growth

According to IQVIA secondary sales data (MAT June 30, 2025), FDC outpaced the Indian Pharmaceutical Market (IPM) with 10.8 per cent growth versus 8.0 per cent for IPM. Its flagship brand, Electral, climbed to 14th place in IPM rankings, up from 18th the previous year. Electral also became the fastest-growing product among IPM’s top 20 and the first FDC brand to cross Rs 6 billion in IPM sales.

Export formulation sales were Rs 420 million, accounting for 6 per cent of total sales, while the API business represented 4 per cent with Rs 260 million in revenue.

Despite short-term supply challenges in emerging markets, FDC maintains a healthy order pipeline and expects improved execution in subsequent quarters.

FDC Limited has reported a steady performance for the quarter ended 30 June 2025 (Q1 FY26), with operating revenue of Rs 6.48 billion, reflecting a year-on-year (YoY) growth of 1.6 per cent.The India formulation business recorded revenue of Rs 5.79 billion, showing a 5.6 per cent YoY rise and contributing 90 per cent to total consolidated sales. The API segment also delivered modest growth of 3.3 per cent YoY, with sales of Rs 260 million. However, export formulations dropped 33.8 per cent YoY to Rs 420 million, while emerging market revenue declined 39 per cent YoY to Rs 260 million due to supply disruptions.The US business showed early signs of recovery, with Rs 116 million in sales during Q1 FY26, representing a 106 per cent YoY growth in direct supplies. This growth follows the resolution of recall-related issues and updated API impurity standards clarified by the US FDA. Despite this progress, overall US business revenue fell 22.2 per cent YoY due to lower profit share from partners caused by reduced sales in FY25.FDC’s EBITDA for the quarter stood at Rs 1.4 billion, with a margin of 21.6 per cent, down from 23 per cent in the previous year. The drop is mainly due to increased strategic expenses, notably a 271.4 per cent YoY surge in R&D expenditure to Rs 85 million and higher employee costs linked to field force expansion and ORS manufacturing capacity enhancements.Business Performance Summary – Q1 FY26 (Rs crore):Net Sales: Rs 648 crore | 1.6% YoY growthIndia Formulations: Rs 579 crore | 5.6% YoY growthUS Formulations: Rs 16 crore | -22.2% YoY declineEmerging Markets: Rs 26 crore | -39.3% YoY declineAPI Sales: Rs 26 crore | 3.3% YoY growthAccording to IQVIA secondary sales data (MAT June 30, 2025), FDC outpaced the Indian Pharmaceutical Market (IPM) with 10.8 per cent growth versus 8.0 per cent for IPM. Its flagship brand, Electral, climbed to 14th place in IPM rankings, up from 18th the previous year. Electral also became the fastest-growing product among IPM’s top 20 and the first FDC brand to cross Rs 6 billion in IPM sales.Export formulation sales were Rs 420 million, accounting for 6 per cent of total sales, while the API business represented 4 per cent with Rs 260 million in revenue.Despite short-term supply challenges in emerging markets, FDC maintains a healthy order pipeline and expects improved execution in subsequent quarters.

Infrastructure Urban

10 Mar 2026

ABB to Invest Rs 6.25 Billion to Expand India Manufacturing

ABB recently announced plans to invest approximately Rs 6.25 billion ($75 million) in India during 2026 to expand its manufacturing footprint and research and development capabilities. The investment follows more than $35 million spent in 2025 and reflects the company’s continued focus on strengthening its ‘local-for-local’ strategy in the country.The investment will support ABB’s Electrification, Motion and Automation businesses and expand manufacturing capacity for infrastructure sectors such as renewable energy, metro rail, data centres and industrial applications. Approximately 300..

Equipment

10 Mar 2026

Six WOLFF Cranes Handle 60,000 m³ Concrete for German Hospital

Six WOLFF tower cranes are playing a key role in constructing a new hospital complex in Memmingen, Germany, supporting large-scale material handling for the project. The facility is being built on a 7.7-hectare site and will feature six floors, around 480 beds and a gross floor area exceeding 75,000 sq m.Building shell works began recently in February 2025. One WOLFF 6531.12 Cross crane supported early site preparation before being dismantled in autumn 2025, while five remaining cranes continue operations. Over an average deployment period of 16 months, the cranes are expected to move approxim..

Equipment

10 Mar 2026

REC Funds Rs 115.6 Million CSR Support for Bihar Eye Hospital

REC recently committed Rs 115.6 million under its Corporate Social Responsibility (CSR) programme for the procurement of clinical and non-clinical equipment at Sankara Eye Hospital in Saharsa, Bihar. The initiative aims to strengthen healthcare infrastructure and improve access to specialised eye care services in the region.A Memorandum of Agreement (MoA) was recently signed between Pradeep Fellows, Executive Director (CSR), REC Limited, and Wg Cdr V. Shankar (Retd), Trustee and Executive Director of Sankara Eye Hospital, at the REC office in the SCOPE Complex, New Delhi.The support is expecte..